Dossier assessment

Fluticasone furoate/umeclidinium/vilanterol (COPD) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2 agonist

Result of dossier assessment:

No statistically significant differences between the treatment groups in the relevant subpopulation of the study included; added benefit not proven

2018-08-16 A G-BA decision was published.

Project no.: A18-15
Commission: Commission awarded on 27.02.2018 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Airways and respiratory system
Note: After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.